Protective effects of pseudoginsenoside-F11 on scopolamine-induced memory impairment in mice and rats.
This study assessed the effects of pseudoginsenoside-F11, a component of Panax quinquefolium L., on scopolamine-impaired memory performance in mice and rats. In the one-trial step-down and step-through passive avoidance tests, although pseudo-ginsenoside-F11 used alone did not affect passive avoidance behaviour in naive mice, the latency of avoidance shortened by intraperitoneal scopolamine (2 mg kg(-1)) was prolonged after intragastric administration of pseudoginsenoside-F11 (2 or 4 mg kg(-1), for five days) in both test systems in mice. In the water-maze test, in mice, the time taken to locate the platform after administration of pseudoginsenoside-F11 was shorter than that after administration of scopolamine (1 mg kg(-1), i.p.). In the two-way active avoidance response test, the latency of avoidance was significantly shorter for the pseudoginsenoside-F11-(1.2 or 2.4 mg kg(-1), i.g. for five days) and scopolamine-treated group than for the group of rats given scopolamine only (2 mg kg(-1), i.p.). The percentage avoidance was also reduced after intraperitoneal injection of scopolamine, but was reversed by administration of pseudo-ginsenoside-F11. These results suggest that pseudoginsenoside-F11 antagonized the memory dysfunction induced by scopolamine. However, the mechanism of the memory facilitative action of pseudoginsenoside-F11 merits further elucidation.
Li
Z
Z
Department of Pharmacology of Chinese Materia Medica, Shenyang Pharmaceutical University, Peoples Republic of China.
Guo
Y Y
YY
Wu
C F
CF
Li
X
X
Wang
J H
JH
D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects; D036145:Ginsenosides; D008297:Male; D008569:Memory Disorders / Q000139:chemically induced / Q000517:prevention & control*; D051379:Mice; D018727:Muscarinic Antagonists / Q000009:adverse effects*; D005894:Panax / Q000737:chemistry; D010946:Plants, Medicinal; D051381:Rats; D017208:Rats, Wistar; D011930:Reaction Time / Q000187:drug effects; D012503:Saponins / Q000494:pharmacology*; D012601:Scopolamine / Q000009:adverse effects*
D036145:Ginsenosides; D018727:Muscarinic Antagonists; D012503:Saponins; D012601:Scopolamine